<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>1825</number>
    <updateDate>2024-07-24T15:23:10Z</updateDate>
    <updateDateIncludingText>2024-07-24T15:23:10Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <originChamberCode>H</originChamberCode>
    <type>HR</type>
    <introducedDate>2023-03-28</introducedDate>
    <congress>118</congress>
    <constitutionalAuthorityStatementText><![CDATA[<pre>[Congressional Record Volume 169, Number 56 (Tuesday, March 28, 2023)][House]From the Congressional Record Online through the Government Publishing Office [<a href="https://www.gpo.gov">www.gpo.gov</a>]By Mr. BLUMENAUER:H.R. 1825.Congress has the power to enact this legislation pursuantto the following:Article 1, Section 8, Clause 3 of the U.S. ConstitutionThe single subject of this legislation is:This legislation clarifies the federal Right to Trystatute.[Page H1528]</pre>]]></constitutionalAuthorityStatementText>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
            <activities>
              <item>
                <name>Referred to</name>
                <date>2023-04-07T14:51:48Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2023-03-28T14:00:15Z</date>
          </item>
        </activities>
      </item>
      <item>
        <systemCode>hsju00</systemCode>
        <name>Judiciary Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2023-03-28T14:00:20Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <actions>
      <item>
        <actionDate>2023-04-07</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2023-03-28</actionDate>
        <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2023-03-28</actionDate>
        <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2023-03-28</actionDate>
        <text>Sponsor introductory remarks on measure. (CR E267)</text>
        <type>IntroReferral</type>
        <actionCode>B00100</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2023-03-28</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2023-03-28</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>B000574</bioguideId>
        <fullName>Rep. Blumenauer, Earl [D-OR-3]</fullName>
        <firstName>EARL</firstName>
        <lastName>BLUMENAUER</lastName>
        <party>D</party>
        <state>OR</state>
        <district>3</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>M000194</bioguideId>
        <fullName>Rep. Mace, Nancy [R-SC-1]</fullName>
        <firstName>Nancy</firstName>
        <lastName>Mace</lastName>
        <party>R</party>
        <state>SC</state>
        <district>1</district>
        <sponsorshipDate>2023-03-28</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>D000631</bioguideId>
        <fullName>Rep. Dean, Madeleine [D-PA-4]</fullName>
        <firstName>Madeleine</firstName>
        <lastName>Dean</lastName>
        <party>D</party>
        <state>PA</state>
        <district>4</district>
        <sponsorshipDate>2023-03-28</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>B001302</bioguideId>
        <fullName>Rep. Biggs, Andy [R-AZ-5]</fullName>
        <firstName>Andy</firstName>
        <lastName>Biggs</lastName>
        <party>R</party>
        <state>AZ</state>
        <district>5</district>
        <sponsorshipDate>2023-03-28</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>C001110</bioguideId>
        <fullName>Rep. Correa, J. Luis [D-CA-46]</fullName>
        <firstName>J.</firstName>
        <lastName>Correa</lastName>
        <party>D</party>
        <state>CA</state>
        <middleName>Luis</middleName>
        <district>46</district>
        <sponsorshipDate>2023-03-28</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects/>
      <policyArea>
        <name>Health</name>
        <updateDate>2023-04-11T20:15:29Z</updateDate>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2023-03-28</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2023-10-10T19:46:25Z</updateDate>
        <text><![CDATA[ <p><b>Right to Try Clarification Act</b></p> <p>This bill specifies that investigational drugs that are provided via the Right to Try pathway are exempt from restrictions that would otherwise apply under the Controlled Substances Act (e.g., restrictions on the use or possession of schedule I controlled substances).</p> <p>The Right to Try pathway allows drug manufacturers to provide certain investigational drugs for which a Phase I clinical trial has been completed, but that have not yet received approval from the Food and Drug Administration, directly to individuals who have imminently life-threatening diseases or conditions and who have exhausted other treatment options and are unable to participate in clinical trials.</p>]]></text>
      </summary>
    </summaries>
    <title>Right to Try Clarification Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <titleTypeCode>45</titleTypeCode>
        <title>Right to Try Clarification Act</title>
        <updateDate>2024-07-24T15:23:10Z</updateDate>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <titleTypeCode>101</titleTypeCode>
        <title>Right to Try Clarification Act</title>
        <updateDate>2024-05-24T13:41:27Z</updateDate>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <titleTypeCode>6</titleTypeCode>
        <title>To clarify that the Federal Right to Try law applies to schedule I substances for which a phase I clinical trial has been completed and to provide access for eligible patients to such substances pursuant to the Federal Right to Try law.</title>
        <updateDate>2024-03-18T20:31:29Z</updateDate>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2023-03-28T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-118hr1825ih/xml/BILLS-118hr1825ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2023-04-07</actionDate>
      <text>Referred to the Subcommittee on Health.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
